Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Diseases
100%
Neoplasm
84%
Melanoma
73%
Malignant Neoplasm
64%
Overall Survival
59%
Chemotherapy
53%
Tumor
50%
Breast Cancer
50%
Cancer
41%
Radiation Therapy
41%
Recurrent Disease
40%
Immunotherapy
39%
Clinical Trial
33%
Progression Free Survival
31%
Non Small Cell Lung Cancer
31%
Oncology
29%
Adverse Event
28%
Lung Cancer
26%
Metastatic Carcinoma
25%
Ovarian Cancer
24%
Arm
24%
Lymph Node
23%
Metastatic Melanoma
23%
Biological Marker
22%
Retroperitoneal Lymph Node Dissection
22%
T Cell
20%
Surgeon
20%
Drug Megadose
19%
Gynecological Oncology
18%
Sentinel Lymph Node
18%
Cervical Cancer
18%
Glioblastoma
18%
Solid Malignant Neoplasm
18%
Colorectal Carcinoma
17%
Quality of Life
17%
Sentinel Node
16%
Prostate Cancer
16%
Lymph Duct
15%
Genetics
15%
Morbidity
15%
Interleukin 2
15%
B-Cell Chronic Lymphocytic Leukemia
15%
Lung
14%
Hazard Ratio
14%
Median Follow Up
14%
Phase II Trials
14%
Biopsy Technique
13%
Intensity Modulated Radiation Therapy
13%
Krukenberg Tumor
13%
Brain Metastasis
13%
Odds Ratio
13%
Neck
12%
Health Care Cost
12%
Infection
12%
Uterine Cancer
12%
COVID-19
12%
Platinum
12%
Cisplatin
12%
Colon Carcinoma
12%
Surgery
11%
Survival Rate
11%
Disease Free Survival
11%
Melanoma Skin Cancer
11%
Pembrolizumab
11%
Chemoradiotherapy
11%
Immune Response
11%
Placebo
10%
Primary Tumor
10%
Adjuvant Therapy
10%
Bevacizumab
10%
Nivolumab
10%
Targeted Therapy
9%
Epidermal Growth Factor Receptor
9%
Adenocarcinoma
9%
Cystectomy
9%
Histology
9%
Gastroesophageal Reflux
9%
Tumor Cell
9%
Cytokine
9%
Antineoplastic Activity
8%
Lobectomy
8%
Squamous Cell Carcinoma
8%
Adolescence
8%
Clear Cell Renal Cell Carcinoma
8%
Pneumonectomy
8%
Magnetic Resonance Imaging
8%
Prognostic Factor
8%
Head and Neck Cancer
8%
Ipilimumab
8%
Cancer Cell
8%
Pelvis
8%
Acute Myeloid Leukemia
8%
Carcinoma
8%
Lymphocyte
8%
Transsphenoidal Surgery
8%
CA-125
7%
Sphincter
7%
Hematopoietic Cell
7%
Computer Assisted Tomography
7%
Cancer Staging
7%
Immunology and Microbiology
T Cell
79%
Immunotherapy
55%
Cytotoxic T-Cell
33%
Overall Survival
30%
Immune Response
29%
Lung
26%
Tumor Cell
19%
Antigen
18%
Interleukin 2
18%
Cytokine
18%
T-Helper Cell
17%
In Vitro
16%
Tumor Antigen
15%
T Cell Receptor
14%
Cancer Immunotherapy
13%
Infection
13%
Peptides
13%
Lymphocyte
13%
Progression Free Survival
13%
Agonist
13%
CD8
12%
Lymph Node
12%
Infectious Disease
12%
Macrophage
12%
CD4
12%
Colorectal Carcinoma
12%
Regulatory T Cell
12%
Dendritic Cell
11%
Interferon Type I
11%
Tumor Vaccine
10%
Monoclonal Antibody
10%
Cancer Cell
10%
Neck
10%
Tumor-Infiltrating Lymphocytes
10%
B Cell
10%
Melanoma Cell
10%
Myeloid
10%
Immunocompetent Cell
9%
Squamous Cell
9%
Neoantigen
9%
Drug Megadose
9%
Natural Killer Cell
8%
Hematopoietic Cell
8%
Tumor Necrosis Factor
8%
CTLA-4
8%
Inflammation
8%
Arm
8%
Adaptive Immune System
8%
Trastuzumab
7%
Antigen Specificity
7%
Programmed Death-Ligand 1
7%
Granulocyte Macrophage Colony-Stimulating Factor
7%
Blood Plasma
7%
Tumor Immunity
7%
Cell Transplantation
7%
Pembrolizumab
6%
Gene Expression
6%
Circulating Tumor Cell
6%
COVID-19
6%
Cytotoxic T Cell
6%
Cell Line
6%
Colon
6%
Phosphotransferase
6%
Kinase
6%
Immune System
6%
CD3 Antigen
6%
Programmed Cell Death
6%
Chemokine
6%
Intravenous Immunoglobulin
5%
Reperfusion
5%
Bevacizumab
5%
Immunogenicity
5%
Disease Free Survival
5%
Ribonucleic Acid
5%
Autoimmunity
5%
CD134
5%
Monocyte
5%
Interleukin 4
5%
Cyclophosphamide
5%
Memory T Cell
5%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
50%
Neoplasm
49%
Diseases
49%
Chemotherapy Regimens
36%
Melanoma
33%
Solid Malignant Neoplasm
31%
Adverse Event
31%
Immunotherapy
29%
Clinical Trial
29%
Overall Survival
27%
Progression Free Survival
25%
Non Small Cell Lung Cancer
23%
Breast Cancer
20%
Biological Marker
18%
Phase II Trials
18%
Lung Cancer
16%
Ovary Cancer
15%
Prostate Cancer
15%
Pharmacokinetics
14%
Monotherapy
14%
Pembrolizumab
14%
Bevacizumab
13%
Uterine Cervix Cancer
12%
Recurrent Disease
12%
Antitumor Activity
11%
Chronic Lymphatic Leukemia
11%
Glioblastoma
11%
Platinum
10%
Interleukin 2
10%
Cisplatin
10%
Placebo
10%
Tolerability
10%
Cytokine
9%
Nivolumab
9%
Colorectal Carcinoma
9%
Retinol
9%
Ipilimumab
9%
Paclitaxel
9%
Monoclonal Antibody
8%
Carboplatin
8%
Maximum Tolerated Dose
8%
Phase I Trials
8%
Metastatic Melanoma
7%
Epidermal Growth Factor Receptor
7%
Brain Metastasis
7%
Renal Cell Carcinoma
7%
Small Cell Lung Cancer
6%
Diarrhea
6%
Remission
6%
Rituximab
6%
Interferon
6%
Receptor
6%
Fluorouracil
6%
Acute Myeloid Leukemia
6%
Carotene
6%
Endometrium Cancer
6%
Pharmacodynamics
5%
Cyclophosphamide
5%
Trastuzumab
5%
Ovary Carcinoma
5%
Disease Exacerbation
5%
Castration Resistant Prostate Cancer
5%
Lenvatinib
5%
Neutropenia
5%
Antigen
5%
Gemcitabine
5%
Metastatic Breast Cancer
5%
Vasculotropin
5%
B Cell Lymphoma
5%
Tumor Growth
5%